A5056023187- Colorectal Cancer Treatments and Studies
- Cancer Genomics and Diagnostics
- Pancreatic and Hepatic Oncology Research
- Lung Cancer Treatments and Mutations
- Gastric Cancer Management and Outcomes
- Genetic factors in colorectal cancer
- Cancer Immunotherapy and Biomarkers
- Hepatocellular Carcinoma Treatment and Prognosis
- Gastrointestinal Tumor Research and Treatment
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Colorectal and Anal Carcinomas
- Gallbladder and Bile Duct Disorders
- Inflammatory Biomarkers in Disease Prognosis
- Biliary and Gastrointestinal Fistulas
- Esophageal Cancer Research and Treatment
- Radiomics and Machine Learning in Medical Imaging
- Pediatric Hepatobiliary Diseases and Treatments
- Metastasis and carcinoma case studies
- Gastrointestinal disorders and treatments
- Cancer, Lipids, and Metabolism
- Immunotherapy and Immune Responses
- Cancer Cells and Metastasis
- Renal cell carcinoma treatment
- Cancer-related Molecular Pathways
- Cancer Diagnosis and Treatment
Vita-Salute San Raffaele University
2022-2025
Istituti di Ricovero e Cura a Carattere Scientifico
2022-2025
Istituto di Ricovero e Cura a Carattere Scientifico San Raffaele
2024-2025
IRCCS Ospedale San Raffaele
2022-2023
San Raffaele University of Rome
2023
Sapienza University of Rome
2017-2022
University of Cagliari
2017-2022
Azienda Ospedaliero-Universitaria Cagliari
2017-2022
Universidade Federal da Bahia
2022
Creative Research Enterprises (United States)
2022
Background: The transmembrane glycoprotein CD44, the major hyaluronan (HA) receptor, has been proven to regulate cell growth, survival, differentiation, and migration. It is therefore widely considered be involved in carcinogenesis. Its role as a new therapeutic target solid tumors under evaluation clinical trials. prognostic value remains controversial. Here, we aimed investigate correlation between CD44 expression clinicopathological features survival metastatic colorectal cancer (mCRC)...
Colorectal cancer (CRC) is a leading tumor worldwide. In CRC, the angiogenic pathway plays crucial role in development and process of metastasis. Thus, anti-angiogenic drugs represent milestone for metastatic CRC (mCRC) treatment lead to significant improvement clinical outcomes. Nevertheless, not all patients respond some develop resistance. Therefore, identification predictive factors able predict response angiogenesis blockade required order identify best candidates receive these agents....
(1) Background: The FLOT regimen, a combination of fluorouracil, leucovorin, oxaliplatin, and docetaxel, is standard treatment for gastric esophagogastric junction cancers, but concerns exist about its potential renal toxicity. exact prevalence severity toxicity need to be well-documented, this knowledge gap could impact the optimal use regimen in clinical practice. We aimed evaluate profile with specific focus on Acute Kidney Disease onset real-life setting explore associated risk factors....
Rechallenge with EGFR inhibitors represents a promising strategy for patients RAS wild type (WT) colorectal cancer (CRC) but definitive selection criteria are lacking. Recently, the WT status on circulating tumor DNA (ct-DNA) emerged as potential watershed this strategy. Our study explored liquid biopsy-driven cetuximab rechallenge in and BRAF selected population.CRC both tissue ct-DNA at baseline receiving were eligible our analysis. Ct-DNA was analyzed RAS-BRAF mutations pyro-sequencing...
Preclinical and clinical data indicate that p53 expression might modulate the activity of epidermal growth factor receptor (EGFR), influencing response/resistance to anti-EGFR monoclonal antibodies. However, association between status outcome has not been clarified yet. In our study, we evaluated role in patients with RAS/BRAF wild-type metastatic colorectal cancer (mCRC) receiving irinotecan/cetuximab an exploratory a validation cohort. was analysed mCRC second-line or third-line...
Introduction Despite available treatment options, pancreatic ductal adenocarcinoma (PDAC) is frequently lethal. Recent immunotherapy strategies have failed to yield any notable impact. Therefore, research focussed on unearthing new drug targets and therapeutic tackle this malignancy attain more positive outcomes for patients.Areas covered In perspective article, we evaluate the main resistance mechanisms immune checkpoint inhibitors (ICIs) approaches circumvent them. We also offer an...
144 Background: The standard treatment of locally advanced rectal cancer (LARC) consists giving preoperative chemoradiation therapy (CT/RT) followed by surgery. Recently, total neoadjuvant (TNT) has shown greater efficacy in terms increasing the rate complete pathological response (pCR) and reducing local systemic relapse. However, based on proposed scheme, risk overtreatment side effects is not negligible. objective this study was to evaluate safety doublet with oxaliplatin-based CT...
Background and Objective: Side effects of drugs administered for breast cancer (BC) according to biology patients’ clinical features can limit patient’s compliance consequently the benefit. Precision medicine is a growing research field improve management BC care evaluating toxicities profile could be an interesting feature in choice personalised treatment. This review aims explore implications tailored anti-cancer therapy knowing safety predisposing factors potential specific drug-related...
Introduction: The association between pancreatic ductal adenocarcinoma (PDAC) and type 2 diabetes mellitus (DM2) has long been evaluated the role of antidiabetic medications such as metformin also investigated. objective this study was to examine insulin use overall survival (OS) in patients with advanced PDAC DM2. Methods: We retrospectively collected data from 164 patients, including an exploratory cohort 96 Medical Oncology Unit, University Hospital Cagliari, Italy, a validation 68 Modena...